sydneyrx2014.com Online ED Pharmacy is an 1st. pharmacy providing a personal service to the community in Australia. Over 50,000 extremely satisfied customers! We're your prescription drug store kamagra australia and have provided trusted service to families in Australia for over 15 years.

Msds/axocet

MATERIAL SAFETY DATA SHEET
Manufacturer's Name:
ALTANA INC.
Divisions:
E. FOUGERA & CO.
PHARMADERM DIVISION

Street Address:
60 BAYLIS ROAD
City, State, Zip Code:
MELVILLE, NEW YORK 11747
Emergency Telephone No.: (800) 424-9300, (631) 454-7677
SECTION 1: IDENTITY
Product Name:
Mupirocin Ointment USP, 2%
Synonyms:
None indicated.
None indicated.
Chemical Family:
Antibacterial.
Formula:
Mupirocin USP, Polyethylene glycol 400NF, and Polyethylene glycol 3350NF.
SECTION 2: SAFETY and HAZARD RATINGS
Health (Acute-Chronic):
Flammability:
Reactivity:
Environment (Air-Water-Soil):
0–1–1
Moderate
Special Hazards:
Not indicated.
Protective Equipment:
General ventilation, eye and hand wash.
SECTION 3: EMERGENCY and FIRST AID PROCEDURES
Flush eyes with plenty of water for at least 15 minutes.
Wash thoroughly with soap and water.
Ingestion:
Give tw o glasses of water and induce vomiting if directed by medical personnel. Never give
anything by mouth to an unconscious person.

Inhalation:
Remove to fresh air. If breathing is difficult, give oxygen. If breathing has stopped, give artificial
respiration.

CALL A PHYSICIAN
CONTACT A POISON CONTROL CENTER
SECTION 4: INGREDIENTS
C A R C IN O G E N
H A Z A R D D A T A
M upirocin
12650-69-0
not established
Polyethylene glycol 400
25322-68-3
not established
Polyethylene glycol 3350
25322-68-3
not established
M SDS# 05A Mupirocin Ointment USP, 2% (November 7, 2005)
Page 1 of 4
SECTION 5: FIRE and EXPLOSION HAZARD DATA
Flash Point:
Not indicated.
Auto-ignition Temperature ºF:
Not indicated.
Flammable Limits in Air by Volume LEL:
Not indicated.
Not indicated.
Extinguishing M edia:
Alcohol foam, Dry chemical, Carbon dioxide, W ater spray.
Special Fire Fighting Procedures:
Use self-contained breathing apparatus when firefighting.
Unusual Fire and Explosion Hazards:
M ay emit toxic fumes when burning.
SECTION 6: REACTIVITY DATA (PH YSICAL H AZARDS)
Stability:
[ X ] Stable
[ ] Unstable
Conditions and Chemicals to Avoid:
Avoid heat, light, oxidants and bases.
Hazardous Combustion or Decomposition Products:
Carbon dioxide, Carbon monoxide.
Hazardous Polymerization:
[ ] M ay Occur
[ X ] W ill Not Occur
SECTION 7: HEALTH H AZARDS
Primary Route(s) of Entry:
Dermal, Ingestion.
Signs and Symptoms of Exposure
a. Overexposure Effects:

M ay cause irritation.
b. Chronic Effects:
b. M ay cause irritation.
1. Inhalation:
None expected.
M ay cause irritation.
M ay cause irritation.
4. Ingestion:
None expected.
5. M edical Conditions
M oderate or severe renal impairment. Sensitivity to any of the ingredients.
Potentially Aggravated:
SECTION 8: SPECIAL PRECAUTIONS and SPILL/LEAK PRO CEDURES
Precautions to be Taken in
Keep container closed w hen not in use. Store at 20º–25ºC (68º–77ºF). Avoid heat,
Handling/Storage:
light, oxidants and bases.
Hygienic Practices:
W ash thoroughly after handling. Use normal hygiene to protect hands, eyes and skin.
W hen M aterial is Released or Spilled:
Assure slippery conditions are nullified. Add sand or dirt. Scoop up and remove.
W ash area w ith soap and water. Dispose of in accordance w ith federal, state and local
regulations.

W aste Disposal M ethods:
Assure conformity with applicable disposal regulations. Dispose of absorbed material
at approved incineration or chemical landfill waste disposal site.

SECTIO N 9: SPECIAL PRO TECTIO N INFO RM ATIO N
Respiratory Protection:
General ventilation.
Skin Protection:
Normal hygiene.
Eye Protection:
Normal hygiene.
Other Protective Clothing or Equipment:
As needed to prevent repeated/prolonged contact.
M SDS# 05A Mupirocin Ointment USP, 2% (November 7, 2005)
Page 2 of 4
SECTION 10: CONTAINERS and LABELING
Special Precautions:
Keep container closed when not in use. Store at 20º–25ºC (68º–77ºF). Avoid
light, heat, oxidants and bases.

Recommended Container:
As supplied (not sold in bulk quantity).
Protect the Container by:
Avoid physical damage and heat.
Container Should be Handled in an Area W ith:
Adequate general ventilation.
The Empty Container is:
Not reusable.
Precautionary Label:
Federal law prohibits dispensing without a prescription. For dermatologic
use. Not for ophthalmic use. (See package insert.)

W arning Placard:
Keep out of reach of children.
IM O Hazard Class #:
Not applicable.
Not applicable.
Hazard Classification:
Not applicable.
DOT Name:
Not applicable.
Shipping Instructions:
Keep aw ay from heat, light, oxidants and bases.
SECTIO N 11: ENVIRO NM ENTAL RISK S
Aquatic Toxicity:
Not indicated.
Biodegradability:
Not indicated.
Partition Coefficient:
Not indicated.
SECTIO N 12: REGULATO RY INFO RM ATIO N
Refer to the follow ing
OSHA Regulations:
If respirator used, 29 CFR 1910.134
references:
DOT Regulations:
Not applicable.
EPA Regulations:
Not applicable.
NDC: 0168-0352-09
0168-0352-22
M SDS# 05A Mupirocin Ointment USP, 2% (November 7, 2005)
Page 3 of 4
SECTION 13: PHYSICAL DATA
Appearance:
A white to off-white, smooth and homogeneous ointment.
M olecular W eight:
Not applicable.
Not determined.
Refractive Index @ 20ºC:
Not determined.
Viscosity @ 25ºC:
> 300,000 cps
Boiling Point:
Not determined.
Freezing/M elting Point:
Not determined.
Congealing Point:
Not determined.
Vapor Pressure (mm Hg @ 20ºC):
Not determined.
Vapor Density (Air=1):
Not determined.
Solubility in W ater:
M iscible.
Solubility in Alcohol:
Not indicated.
Solubility in Oil:
Not indicated.
Solubility in O ther:
Not indicated.
Specific Gravity (H2O=1):
~1.1 @ 60ºC
% Volatile by Volume:
Negligible.
Evaporation Rate (Ether=1):
Not indicated.
Date of Preparation/Change:
Revision # 0
Replaces
November 7, 2005
The information presented herein relates to the specific material described and may not be valid for this material used in
combination with any other materials or in any process. This information is, to the best of our knowledge, accurate and reliable on
the date compiled. W e make no representation, w arranty or guarantee as to its accuracy, reliability or completeness.

It is the reader's responsibility to ascertain whether the information supplied is suitable and complete for that person's specific
uses. This M aterial Safety Data Sheet was prepared for ALTANA INC. by:
COM PLIANCE INNOVATIONS, INC.
706 Route 15 South, Suite 207
Lake Hopatcong, New Jersey 07849
973-663-1120 • fax 973-663-2378
helpdesk@ chemply.com
M SDS# 05A Mupirocin Ointment USP, 2% (November 7, 2005)
Page 4 of 4

Source: http://hostmaster.amatheon.com/msds/Mupirocin_Oint_2_Altana.pdf

Tacrofort 5 mg pi.cdr

médico se você apresentar algum desses sintomas. O tratamento com carboidratos (668 Kcal, 85% de carboidratos) fez com que a AUC e randomizados. O grupo controle ativo foi tratado com regime de Tacrofort irá diminuir a sua imunidade e você estará sujeito a contrair Cmáx médias decrescessem 28% e 65%, respectivamente. Em imunossupressão baseado em ciclosporina. Ambos estudos utilizaram

Microsoft word - pan-arvo 2006_final.doc

Pan American Association of Ophthalmology PAN-ARVO Day Final Program Saturday, April 29, 2006 Renassaince Hotel, Fort Lauderdale G. Jimenez - IOL Power Calculation after Non-Laser Refractive Surgery G. Villanueva - Efficacy and Safety of Artisan Lens in High Myopia J.D. Larios - Confocal Microscopy Findings after PRK and Amniotic Membrane Transplantation N.J. Cortes - Topograp

Copyright © 2010-2014 Pdf Medical Search